Molecular Basis for Inhibition of the Na+/Citrate Transporter NaCT (SLC13A5) by Dicarboxylate Inhibitors
Ana M Pajor1, Cesar A de Oliveira2, Kun Song2
1University of California San Diego (A.M.P.), Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California; Cardiovascular, Metabolic and Endocrine Disease Research Unit (K.S., K.H., D.M.E.), Pfizer Worldwide Research and Development, Cambridge, Massachusetts; Center of Chemistry Innovation and Excellence (C.A.O., V.S.), Pfizer Worldwide Research and Development, Groton, Connecticut apajor@ucsd.edu.
Abstract:
The Na+/citrate transporter, NaCT (SLC13A5), is a therapeutic target for metabolic diseases. Citrate is an important signaling molecule that regulates the activity of lipid- and glucose-metabolizing enzymes in cells. Previous studies identified two compounds, PF-06649298 (compound 2: ) and PF-06678419 (compound 4: ), that inhibit human NaCT with high affinity, and one of the compounds demonstrated specificity relative to other SLC13 family members. Here we use molecular modeling and site-directed mutagenesis of hNaCT followed by transport characterization and cell-surface biotinylation to examine the residues involved in inhibitor binding and transport. The results indicate that residues located near the putative citrate binding site, G228, V231, V232, and G409, affect both citrate transport and inhibition of citrate uptake by compounds 2: and 4: V231 appears to distinguish between compounds 2: and 4: as inhibitors. Furthermore, residues located outside of the putative citrate binding site, Q77 and T86, may also play a role in NaCT inhibition by compounds 2: and 4: Our results provide new insight into the mechanism of transport and inhibition in NaCT and the SLC13 family. These findings should provide a basis for future drug design of SLC13 inhibitors.
Insights
Researchers investigated the Na+/citrate transporter (NaCT) and its inhibitors. Key residues affecting citrate transport and drug binding were identified, paving the way for improved metabolic disease therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- The Na+/citrate transporter (NaCT, SLC13A5) is crucial for metabolic regulation and a target for treating metabolic diseases.
- Citrate acts as a signaling molecule influencing lipid and glucose metabolism.
- Previous research identified two high-affinity NaCT inhibitors, PF-06649298 and PF-06678419.
Purpose of the Study:
- To elucidate the molecular mechanisms of NaCT inhibition and transport.
- To identify specific amino acid residues involved in inhibitor binding and substrate transport.
- To provide a foundation for designing novel SLC13 inhibitors.
Main Methods:
- Molecular modeling of human NaCT (hNaCT).
- Site-directed mutagenesis of hNaCT residues.
- Transport assays to characterize citrate uptake.
- Cell-surface biotinylation to assess protein localization.
Main Results:
- Residues G228, V231, V232, and G409 near the citrate binding site impact both transport and inhibitor binding.
- Residue V231 differentiates the inhibitory effects of PF-06649298 and PF-06678419.
- Residues Q77 and T86, outside the putative citrate site, also influence NaCT inhibition.
Conclusions:
- Specific residues within and outside the citrate binding pocket are critical for NaCT function and inhibition.
- Understanding these interactions advances knowledge of NaCT transport mechanisms.
- These findings support the rational design of NaCT-targeting drugs for metabolic disorders.
More Related Videos
09:12Selection of Transporter-Targeted Inhibitory Nanobodies by Solid-Supported-Membrane SSM-Based Electrophysiology
Published on: May 3, 2021
07:38Functional Characterization of Na+/H+ Exchangers of Intracellular Compartments Using Proton-killing Selection to Express Them at the Plasma Membrane
Published on: March 30, 2015
Related Concept Videos
Secondary Active Transport
Secondary Active Transport
The Significance of Membrane Transport
Transporters facilitate either an active or passive movement of solutes. They can allow a single-molecule transport down its...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Active Transport
Primary active transporters, like Na+, K+ and -ATPase, directly utilize ATP to move ions across the membrane. These transporters play significant roles in various physiological processes. For instance, Na+, K+ and -ATPase maintain...
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
